Engineering CAR T cells to produce fusion proteins combining a cytokine and an antibody has shown to enhance efficacy and safety in animal models of prostate and ovarian cancer. The post CAR T Cells Engineered with Fusion Proteins Improve Solid Tumor Response appeared first on Inside Precision Medicine.
